These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 25943532)

  • 1. Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.
    George DJ; Nabhan C; DeVries T; Whitmore JB; Gomella LG
    Cancer Immunol Res; 2015 Sep; 3(9):1063-9. PubMed ID: 25943532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
    Small EJ; Schellhammer PF; Higano CS; Redfern CH; Nemunaitis JJ; Valone FH; Verjee SS; Jones LA; Hershberg RM
    J Clin Oncol; 2006 Jul; 24(19):3089-94. PubMed ID: 16809734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Kantoff PW; Higano CS; Shore ND; Berger ER; Small EJ; Penson DF; Redfern CH; Ferrari AC; Dreicer R; Sims RB; Xu Y; Frohlich MW; Schellhammer PF;
    N Engl J Med; 2010 Jul; 363(5):411-22. PubMed ID: 20818862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
    Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
    Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.
    GuhaThakurta D; Sheikh NA; Fan LQ; Kandadi H; Meagher TC; Hall SJ; Kantoff PW; Higano CS; Small EJ; Gardner TA; Bailey K; Vu T; DeVries T; Whitmore JB; Frohlich MW; Trager JB; Drake CG
    Clin Cancer Res; 2015 Aug; 21(16):3619-30. PubMed ID: 25649018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.
    Small EJ; Higano CS; Kantoff PW; Whitmore JB; Frohlich MW; Petrylak DP
    Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):259-64. PubMed ID: 24957547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.
    Schellhammer PF; Chodak G; Whitmore JB; Sims R; Frohlich MW; Kantoff PW
    Urology; 2013 Jun; 81(6):1297-302. PubMed ID: 23582482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.
    Twardowski P; Wong JYC; Pal SK; Maughan BL; Frankel PH; Franklin K; Junqueira M; Prajapati MR; Nachaegari G; Harwood D; Agarwal N
    Cancer Treat Res Commun; 2019; 19():100116. PubMed ID: 30682445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.
    Bilen MA; Hess KR; Subudhi SK; Aparicio A; Kim J; Zurita-Saavedra AJ; Araujo JC; Corn PG; Stover J; Lin SH; Logothetis CJ; Tu SM
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):583-589. PubMed ID: 28730293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
    McNeel DG; Gardner TA; Higano CS; Kantoff PW; Small EJ; Wener MH; Sims RB; DeVries T; Sheikh NA; Dreicer R
    Cancer Immunol Res; 2014 Oct; 2(10):988-99. PubMed ID: 25189164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
    Higano CS; Schellhammer PF; Small EJ; Burch PA; Nemunaitis J; Yuh L; Provost N; Frohlich MW
    Cancer; 2009 Aug; 115(16):3670-9. PubMed ID: 19536890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
    Beer TM; Bernstein GT; Corman JM; Glode LM; Hall SJ; Poll WL; Schellhammer PF; Jones LA; Xu Y; Kylstra JW; Frohlich MW
    Clin Cancer Res; 2011 Jul; 17(13):4558-67. PubMed ID: 21558406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
    Sartor O; Armstrong AJ; Ahaghotu C; McLeod DG; Cooperberg MR; Penson DF; Kantoff PW; Vogelzang NJ; Hussain A; Pieczonka CM; Shore ND; Quinn DI; Small EJ; Heath EI; Tutrone RF; Schellhammer PF; Harmon M; Chang NN; Sheikh NA; Brown B; Freedland SJ; Higano CS
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):517-526. PubMed ID: 32111923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
    Gardner TA; Elzey BD; Hahn NM
    Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX; Fong L; Small EJ
    Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
    Higano CS; Armstrong AJ; Sartor AO; Vogelzang NJ; Kantoff PW; McLeod DG; Pieczonka CM; Penson DF; Shore ND; Vacirca J; Concepcion RS; Tutrone RF; Nordquist LT; Quinn DI; Kassabian V; Scholz MC; Harmon M; Tyler RC; Chang NN; Tang H; Cooperberg MR
    Cancer; 2019 Dec; 125(23):4172-4180. PubMed ID: 31483485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sipuleucel-T for the treatment of advanced prostate cancer.
    Frohlich MW
    Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment options for castration-resistant prostate cancer.
    Simondsen K; Kolesar J
    Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.